Current Status of Celiac Disease Drug Development

Abstract

Celiac disease (CeD) is one of the most common immune-mediated diseases. Symptoms and disease activity are incompletely controlled by the gluten-free diet, which is currently the only available therapy. Although no therapies are yet approved, there is a growing field of candidates and an improving understanding of the regulatory pathway. In this review, we briefly discuss the epidemiology, pathophysiology, and current treatment paradigm for CeD. We also review the major classes of therapies being considered for CeD and discuss extensively what is known and can be surmised regarding the regulatory pathway for approval of a CeD therapeutic. The coming years will see an increasing number and diversity of potential therapies entering clinical trials and hopefully the first approved agents targeting this significant unmet medical need. Although biomarkers including histology and serology will always be important in therapeutic clinical trials, they currently lack the necessary evidence linking them to improved patient outcomes required for use as primary outcomes for drug approval. For this reason, patient-reported outcomes will likely be primary end points in Phase III CeD trials for the foreseeable future.

Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials

“…Almost two-thirds of patients with coeliac disease feel that there is a need for alternative therapies, often driven by persistent symptoms or a desire to increase their gluten intake 10. Several pharmacological therapies are emerging and are in various stages of clinical development in response to this medical need 7. Although the FDA and European Medicines Agency have increased their collaboration over the years, it is important to note that the two agencies may hold different views on the designation of coeliac disease therapies (eg, drugs vs medical devices), as well as on the criteria for approval of these therapies 50.…”

“…In line with FDA recommendations for a paradigm shift from mainly disease-oriented care towards a patient-centred care for chronic medical disorders such as coeliac disease, it is likely that PROs will become primary outcome measures in coeliac disease registration trials 7 15. A PRO is any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response 15.…”

Coeliac disease: a unique model for investigating broken tolerance in autoimmunity

“…Despite sequence similarity of the α‐ and ω‐gliadin epitopes, their TCR repertoires are unique and show biased use of different TRAV and TRBV genes 49 . Appreciating the uniqueness of these distinct immunodominant epitopes has been crucial for the development of peptide‐specific applications, including a novel CD diagnostic based on detection of whole blood IFN‐γ release after gluten challenge 40 and a tolerogenic therapeutic vaccine (Nexvax2) 50 …”

Enzyme Therapy that Can Digest the Toxic Motifs of Gluten as an Aid in the Management of Celiac Disease

“…A number of approaches in non-dietary treatments have been investigated around the world, including the enzymatic detoxification of ingested gluten, a vaccine to induce gluten tolerance, inhibitors of the HLA DQ2 and DQ8 proteins or tissue transglutaminase antibodies (tTG) and others [12].…”